Rare Sugar Members Release Glucagon-Like Peptide-1 and Inhibit Food Intake in Mice

If you formulate reduced-sugar products, you already know D-allulose. It delivers sweetness without the calories. A new study in mice adds another reason to track this ingredient: D-allulose triggers release of active GLP-1 and suppresses food intake.

The paper, published in Nutrients (DOI: 10.3390/nu17071221), belongs to the growing research on rare sugars. These compounds occur naturally in tiny amounts. They offer sweetness and low calorie content, which is why many formulators treat them as next-generation functional sugars. This study asked whether that functional story includes appetite control.

Background

Rare sugars are nature’s minority players. They show up in small quantities, yet taste sweet and carry few calories. That combination has put them on the radar for better-for-you product development. D-allulose is the best-known member, but the class includes other sugars too.

This study focused on whether rare sugars do more than taste good. Specifically, it tested D-allulose and its effect on GLP-1, a gut hormone tied to insulin release and appetite signaling.

What the researchers did

The team gave mice a single oral gavage of D-allulose at 1 g/kg and 3 g/kg. Then they measured active GLP-1 in portal vein plasma. Portal vein sampling matters because GLP-1 degrades quickly. Measuring there catches the gut’s early signal.

They also tracked short-term food intake. To test whether GLP-1 caused the eating behavior, they repeated the experiment with exendin(9-39), a GLP-1 receptor antagonist.

Key findings

D-allulose worked. Both doses significantly raised active GLP-1 in the portal vein. Food intake dropped too, and the effect scaled with dose. When the researchers blocked GLP-1 receptors with exendin(9-39), the food intake suppression disappeared. That is strong evidence. The satiety signal runs through GLP-1.

Condition	Portal active GLP-1	Short-term food intake
D-allulose, 1 g/kg	Significant increase	Suppressed
D-allulose, 3 g/kg	Significant increase	Dose-dependent suppression
D-allulose + exendin(9-39)	—	Suppression blocked

The antagonist result is the key piece. It separates correlation from causation. D-allulose did not rely on a general aversive effect. Block the receptor, and the effect vanishes.

What it means for manufacturers

This data gives formulators a reason to think beyond sweetness. D-allulose already fits low-sugar and clean-label products. If human trials repeat these effects, it could support satiety positioning, portion control, and glycemic management.

The authors describe rare sugars as promising functional food ingredients for preventing overeating and promoting blood glucose control. That aligns with current market interest in GLP-1-related nutrition. You can formulate with D-allulose today. Later, you may be able to make stronger claims.

Keep the dose-response in mind. The effect was dose-dependent in mice. That raises practical questions about human serving sizes and timing. A small sprinkle in a cookie may not match the levels used here. Beverages, shots, or meal replacements might deliver a more meaningful dose.

FAQ

Will allulose curb appetite in humans?

Not proven yet. This is an acute mouse study. It shows a clear mechanism, but human clinical data is needed before any satiety claim.

How does D-allulose raise GLP-1?

The paper demonstrates release, not the full molecular trigger. The exact sensor and signaling route still need work.

Should I switch to D-allulose over other rare sugars?

The strongest evidence in this study is for D-allulose. Other rare sugars belong to the same family, but they may act differently.

The bigger picture

This study does not prove allulose is a hunger drug. It does something more valuable for product developers. It identifies a concrete pathway. Active GLP-1 rises. Food intake falls. Block the receptor, and the effect disappears. That is the kind of mechanistic data that moves ingredients forward.

Human trials will decide where this goes. For now, D-allulose stands out as a sugar with metabolic potential, not just a sweetener substitute. Keep an eye on the follow-up studies. This space is moving fast.